ArticleJournal of the National Cancer Institute2022
Identifying Novel Causes of Cancers to Enhance Cancer Prevention: New Strategies Are Needed.
Article in Journal of the National Cancer Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 74 citations in OpenAlex.
- Pyrimidine derivatives as anticancer agents targeting kinases: design strategies, biological evaluation, and structure-activity relationship insights.Molecular diversity · 2026Review
- The cocrystals of isorhamnetin and isoliquiritigenin with 4,4'-bipyridine: system characterization, stability, dissolution and anticancer activity.RSC advances · 2026Article
- Article
- Accelerating discovery of cancer causes for prevention in the era of rising early-onset cancers.Cell · 2026Review
- Tumour promotion through the lens of evolution.Nature · 2026Review
- Why can't epidemiology be automated (yet)?International journal of epidemiology · 2026Article
- Latent profile analysis and influencing factors of health literacy among family caregivers of cancer patients.Frontiers in public health · 2026Article
- The early-onset cancer epidemics: evidence synthesis using the prospective cohort incident-tumor biobank method.European journal of epidemiology · 2025Review
- Exosomal microRNA Panels for Detecting Early-Stage Non-Small Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Biomarkers for Personalised Primary or Secondary Prevention in Cardiovascular Diseases: A Rapid Scoping Review.International journal of molecular sciences · 2025Article
- Article
- Unlocking the potential of tumor-derived DNA in urine for cancer detection: methodological challenges and opportunities.Molecular oncology · 2025Review
- Article
- Modifiable factors affects cancer-specific survival: findings from a large population-based prospective cohort study.Journal of translational medicine · 2025Article
- Anti-tumor efficacy and safety of AEV01 in preclinical glioblastoma and hepatocellular carcinoma models.Scientific reports · 2025Article
- Geographic and age-related variations in mutational processes in colorectal cancer.medRxiv : the preprint server for health sciences · 2025Article
- Effect of weight loss following Roux-en-Y gastric bypass on cancer risk: A Mendelian randomization study.Medicine · 2025Article
- Article
- Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives.Cancers · 2024Review
- Global Research Trends and Recent Advances in Medicinal Plant-Synthesized Nanoparticles for Cancer Treatment.Plants (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The burden of cancer from a clinical, societal, and economic viewpoint continues to increase in all parts of the world, along with much debate regarding how to confront this. Projected increases in cancer indicate a 50% increase in the number of cases over the next 2 decades, with the greatest proportional increase in low- and medium-income settings. In contrast to the historic high cancer burden due to viral and bacterial infections in these regions, future increases are expected to be due to cancers linked to westernization including breast, colorectum, lung, and prostate cancer. Identifying the reasons underlying these increases will be paramount to informing prevention efforts. Evidence from epidemiological and laboratory studies conducted in high-income countries over the last 70 years has led to the conclusion that approximately 40% of the cancer burden is explained by known risk factors-the 2 most important being tobacco and obesity in that order-raising the question of what is driving the rest of the cancer burden. International cancer statistics continue to show that approximately 80% of the cancer burden in high-income countries could be preventable in principle, implying that there are important environmental or lifestyle risk factors for cancer that have not yet been discovered. Emerging genomic evidence from population and experimental studies points to an important role for nonmutagenic promoters in driving cancer incidence rates. New research strategies and infrastructures that combine population-based and laboratory research at a global level are required to break this deadlock.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.